New therapies for onychomycosis

Journal of the American Academy of Dermatology

Volumn 35, Issue 3 PART II, 1996, Pages

  Odom, Richard B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE DERIVATIVE; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; TERBINAFINE; TRIAZOLE DERIVATIVE;

DRUG EFFICACY; DRUG INDUCED DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; ONYCHOMYCOSIS; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; FLUCONAZOLE; HUMANS; ITRACONAZOLE; NAPHTHALENES; ONYCHOMYCOSIS;

EID: 0029758477     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0190-9622(96)90067-5     Document Type: Article

References (30)

1. Roberts DT. Oral therapeutic agents in fungal nail disease. J Am Acad Dermatol 1994;31:878-81.
2. Piérard G, Arrese-Estrada J, Piérard-Franchimont C. Treatment of onychomycosis: traditional approaches. J Am Acad Dermatol 1993;29:S41-5.
3. Scher RK. Diseases of the nails. In: Conn H, editor. Current therapy. Philadelphia: W.B. Saunders, 1990:736.
4. Davies RR, Everall JD, Hamilton E. Mycological and clinical evaluation of griseofulvin for chronic onychomycosis. Br Med J 1967;3:464-8.
5. Frain-Bell W, Riddell RW, Stevenson CJ, et al. Chronic ringworm infection of the skin and nails treated with griseofulvin. Lancet 1960;1:1141-7.
6. Davies RR. Griseofulvin. In: Speller DCE, editor. Antifungal chemotherapy. New York: John Wiley, 1980:149-82.
7. Dollery C. Griseofulvin. In: Therapeutic drugs. Edinburgh: Churchill Livingstone, 1991:G66-9.
8. Janssen PAJ, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med 1983;74:80-5.
9. Hay RJ. Risk/benefit ratio of modern antifungal therapy: Focus on hepatic reactions. J Am Acad Dermatol 1993;29: S50-4.
10. Odds FC. Spectrum of orally active antifungals. J Eur Acad Dermatol Venereol 1993;2(suppl 1):S12-8.
11. Powderly W, Finkelstein D, Feinberg J. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced HIV infection. N Engl J Med 1995;332:700-5.
12. Cameron ML, Schnell WA, Bruch S, et al. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993;37:2449-53.
13. Kuokkanen K, Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992;3:115-7.
14. Fraki J, Heikkila H, Kero M, et al. Fluconazole in the treatment of onychomycosis: an open non-comparative multicenter study with oral 150-mg fluconazole once weekly. In: Future trends in the treatment of dermatomycoses. Dermatology 2000, Vienna, abstract book, poster, May 1993.
15. Osterloh IH. Safety. In: Powderly WB, Van Wout JW, editors. Fluconazole. Carnforth, United Kingdom: Marias Press, 1992:40.
16. Bickers DR. Antifungal therapy: potential interactions with other classes of drugs. J Am Acad Dermatol 1994;31:S87-90.
17. Willemsen M, De Doncker P, Willems J, et al. Postrreatment itraconazole levels in the nail. J Am Acad Dermatol 1992;26:731-5.
18. Data on file, Janssen Pharmaceutica (Beerse, Belgium).
19. Arenas R, Dominguez-Cherit J, Fernandez LM. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995;34:138-43.
20. Roseeuw D, De Doncker P. New approaches to the treatment of onychomycosis. J Am Acad Dermatol 1993; 29: S45-50.
21. Alcantara R, Garibay JM. Itraconazole therapy in dermatomycoses and vaginal candidiasis: effects and adverse effects profile in a large multi-center study. Adv Ther 1988; 5:326-34.
22. De Doncker P, Van Lint J, Dockx P, et al. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis 1995;56: 180-3.
23. De Doncker P, Decroix J, Piérard G, et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996; 132:34-41.
24. Goodfield, MJD. Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol 1992;126(suppl 39):33-5.
25. Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995;32:750-3.
26. Hofmann H, Bräutigam M, Wiedinger G, et al. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995;131:919-22.
27. Haneke E, Tausch I, Bräutigam M, et al. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995;32:72-7.
28. Villars VV, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992;126(suppl 39):61-9.
29. Stricker BH, De-Jong PA, Schreuder F, et al. Loss of taste sensation in terbinafine administration. Ned Tijdschr Geneeskd 1992;136:2438-400.
30. Kovacs MJ, Alshammari S, Guenther L, et al. Neutropenia and pancytopenia associated with oral terbinafine. J Am Acad Dermatol 1994;31:806.